Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2019-02-28 Capital/Financing Update
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or agreements by a company. The content describes a material definitive agreement between Apellis Pharmaceuticals and SFJ Pharmaceuticals Group regarding development funding for a drug candidate. It details the terms of the agreement, funding amounts, milestones, and termination conditions. There are no financial statements or comprehensive financial performance data included. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial report. Instead, it is an announcement of a significant financing and collaboration agreement. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2019-02-28 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Registration Statement on Form S-3 filed with the SEC by Apellis Pharmaceuticals, Inc. It is a registration statement related to securities offerings, including debt securities, common stock, preferred stock, units, and warrants. The document includes details about the registration fee, offering amounts, and legal disclaimers typical of SEC registration statements. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising and securities registration. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a Form S-3 post-effective amendment related to securities offerings.
2019-02-26 English
10-K
Annual Report FY 2018
2019-02-26 English
POSASR
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Registration Statement on Form S-3 filed with the SEC by Apellis Pharmaceuticals, Inc. It includes detailed information about the registration of securities for offering, including debt securities, common stock, preferred stock, units, and warrants. The document is a registration statement amendment related to securities offerings and capital raising activities. It is not a financial report, earnings release, or management discussion. It is clearly related to capital/financing updates and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or a certification, supporting a high confidence level.
2019-02-26 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Apellis Pharmaceuticals, Inc. It registers securities under the Securities Act of 1933, specifically related to stock incentive plans and employee stock purchase plans. The document includes details about the securities to be registered, calculation of registration fees, incorporation by reference of other filings, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual registration statement filing.
2019-02-26 English
AMENDMENT NO. 2
Major Shareholding Notification
2019-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.